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Abstract 
 
Multiple Sclerosis (MS) is a chronic disease of the Central Nervous System 
(CNS) characterized by inflammatory demyelination. The resulting effects on neuronal 
conduction lead to functional deficits affecting gait, vision, muscular function, and other 
basic processes, which occur in a relapsing/remitting or progressive manner. A number of 
the most effective treatments for MS are formulations of the human signaling molecule 
Interferon-β (IFN-β). However, these treatments’ mechanism of action in the context of 
MS is not well established. We have previously identified a population of effector CD-4+ 
T cells that self-regulates via up-regulation of the immunosuppressive cytokine 
interleukin-10 (IL-10) in a mouse model of MS. We hypothesize that induction of IL-10+ 
T helper type 1 (Th1) cells is a key contributor to the efficacy of IFN-β therapy in MS. If 
this population is increased in MS patients receiving IFN-β treatment, this would strongly 
support a contribution to clinical benefit. If these cells are essential in IFN-β’s 
mechanism of action, IL-10+ Th1 cells could be used as a marker of therapeutic efficacy 
and as a target for drug development.  
 
We have developed a methodology to study effector CD-4+ T cells ex vivo to 
examine the expression patterns of the cytokines (signaling molecules) IL-10, 
Interleukin-17 (IL-17), and Interferon-γ (IFN-γ) by flow cytometry and enzyme linked 
immunosorbent assays (ELISAs) to establish the presence or absence of the target IL-10+ 
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population and its characteristics. We have analyzed this population in 3 MS patients pre- 
and post-initiation of IFN-β therapy, as well as in an additional cohort of 2 MS patients 
pre- and post-initiation of the alternative MS treatment copaxone. Our data demonstrates 
no alteration in the IFN-γ+/IL-10+ double positive population after IFN-β or copaxone 
treatment.  
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Chapter 1:  Introduction 
 
Multiple Sclerosis (MS) is a devastating disease of the central nervous system 
(CNS) which has major effects on patients’ lives. The most dramatic symptom which can 
occur in MS is paralysis, but gait, vision, cognitive function, and balance, among other 
processes, are commonly affected
1
. Perhaps surprisingly for a disease with such severe 
symptoms, it is predominantly recorded in modern history. While the first ostensible case 
of MS occurred in 1395 in Holland, the first concrete medical definition for the disease 
was developed by Charcot, in 1868
2
. There is no established cause for MS, but simply 
both anecdotal and published correlations which remain more or less controversial, 
among which are correlations with high latitudes and the developed world
1,3,4,5
. In the 
United States, there may be 350,000 MS cases, or more
3
. A similar number of cases have 
been reported in Europe
4
. Globally, over 2.1 million cases are estimated
5
. In Denmark, 
154.5 cases per 100,000 people have been reported, or an incidence of over 1.5%
6
. MS 
may be increasing in incidence in the developed world, but this remains uncertain. 
Gender bias is a feature of multiple sclerosis, with three or more women suffering from 
the disease for every two men
1
.There is no cure for the disease, current treatments simply 
limit disease progression, without reversing pathology in progressive forms of the 
disease. MS treatments possess major side effects. 
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A debate in the field is whether MS is one disease or many, as it presents in a 
number of different ways
1
. 55% of cases are relapsing/remitting (RRMS), which 
phenotype is characterized by attacks followed by nearly complete recovery or residual 
deficits
1
. RRMS patients typically advance to secondary progressive disease (SPMS, 30% 
of total cases), which exhibits slow, constant deterioration
1
. 10% of total MS cases are 
primary progressive (PPMS), with a similar course to SPMS, and 5 % benign 
(characterized by little to no deterioration), as well as rare acute cases (which progress 
more rapidly)
1
. Finally, clinically isolated syndromes, such as neuromyelitis optica, often 
present before the defined onset of MS, begging the question of how they relate to MS
1
. 
This complexity of clinical presentation leads to the question of whether different triggers 
lead to each form of MS; however, what initiates MS is still unknown. 
 
MS is believed to be caused by an attack by the body’s own immune system  
(termed an autoimmune response) against the myelin sheath of neurons, which is 
essential for proper neuronal conduction
1
. This results in impaired neuronal function, 
neuronal death, and “scarring” (gliosis, or recruitment of glial, supporting cells to form a 
scar-like site)
1
. The myelin sheath is destroyed in parts of the brain in MS, which can be 
visualized by a contrast agent called gadolinium. Areas of active demyelination appear as 
bright spots on MRI, while so-called “black holes” represent regions with axon (and 
myelin) loss
1
. It is believed that exacerbations (attacks in the relapsing/remitting form of 
MS) and new symptoms correlate with demyelination of the regions of the CNS 
corresponding to those functions affected. Active lesions exist during periods of silent 
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disease, leading to the idea that clinical disease occurs when the built-in functional 
reserve in the CNS is eroded. The essential problem of MS is that once a neuron in the 
CNS is lost, it will never be replaced. 
 
Disease:  As MS is an immune mediated disease, the constraints on the 
development of an immune response in the CNS are essential to a discussion of the 
disease. The master regulators and effectors of a specific (or adaptive) immune response 
are T cells, and T cell regulation is the crux of tolerance and autoimmunity. During 
development of T cells in the thymus, negative selection takes place to eliminate or 
anergize (render unreactive) autoreactive T cells, or to divert them into an 
immunosuppressive regulatory T cell lineage (Treg). Despite the presence of any 
“escaped” potentially autoreactive T cells, further barriers remain to an immune response 
in the CNS. Regions of the body like the CNS are considered to be “immunoprivileged,” 
meaning that immune responses are prevented or heavily restricted within the site. One 
major element of CNS privilege is the Blood Brain Barrier (BBB), an impressively 
restrictive barrier to cells and molecules passing into the CNS. However, over the last 
few decades, it has become clear that this immunoprivilege is more tenuous than 
previously thought and that the BBB is not completely impermeable to immune cells
7
. 
For MS to develop, these hurdles must be surmounted by autoreactive T cells. 
 
Two key steps in MS development are access to the brain for autoreactive T cells 
and the development and maintenance of an autoreactive response, as even healthy 
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individuals appear to have myelin specific, potentially autoreactive T cells
8
. With regard 
to the first, as stated, the BBB is a highly stringent regulator of substances and cells 
entering the CNS. Though there are now publications demonstrating that effector T cells 
may be able to conduct CNS surveillance under homeostatic conditions, naïve (or 
antigen-“target”-inexperienced) T cells do not gain access to the CNS7. While alteration 
of the BBB’s permeability to T cells does appear to occur in MS,  the key step in MS 
development may be the generation of memory T cells which are reactive with myelin, as 
might occur when cross reactive virus specific effector T cells are activated in infection
9
. 
Such cells could pass the BBB to start an immune response in the CNS. Regarding the 
second key requirement, immune responses are not intended to continue indefinitely and 
immune cells have a finite lifespan, while Tregs begin to develop in an environment with 
excessive tissue damage, late in the immune response
10
. Thus, MS does not only require 
an autoimmune response, but also dysregulation of the controls that would terminate the 
response, at least in the case of progressive disease. The existence of relapsing disease 
likely implies that there is control of the disease at points, but something breaks that 
tenuous tolerance. Such hints provide hope for immunotherapies to restore tolerance in 
MS. 
 
Epidemiology: While MS’ etiology remains unclear, a number of studies and 
anecdotes provide possible clues to its etiology. The Faroe Islands, situated halfway 
between Norway and Iceland, were subjected to a major influx of soldiers during World 
War II, and MS appeared soon after among the natives
1
. This would support an infectious 
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agent as the trigger for MS as this short time frame is likely insufficient for changes in 
hygiene, diet, and similar factors to take effect. A viral infection could potentially break 
tolerance for myelin by inappropriately over-activating the immune system or activating 
cross-reactive T cells coincidentally specific for both a viral antigen and a myelin 
antigen. Since the 1960’s and perhaps earlier, viruses have been considered prime 
candidates in the genesis of MS
11
. Studies have shown measles virus specific antibodies 
in the cerebrospinal fluid and serum, circulating Epstein Barr virus specific CD-8 T cells, 
and hepatitis G virus DNA integrated into cells in the CNS in MS patients
11,12,13
. 
However, correlating infectious agents with MS is often confounded by better reporting 
and diagnosis after development of a modern infrastructure, as is true for other products 
of development like advanced hygiene (which could lead to altered development of the 
immune system because of less microbial stimulation). Additionally, a single virus has 
not been reproducibly found in the human CNS. 
 
An alternative hypothesis recently advanced is that an unnatural amino acid 
(azeditine-2-carboxylic acid) in sugar beets resembling proline causes altered self-
peptides which are recognized by the immune system or promote altered stability of 
myelin, leading to autoimmunity
14
. In the case of the altered amino acid model for MS, if 
this novel amino acid were incorporated into antigens for T cells, no regulatory 
mechanisms would have deleted T cells specific for these antigens as they had not 
previously been seen by the body. Regarding altered stability of myelin, if myelin 
breakdown occurred at the wrong time, or if myelin breakdown products arrived at the 
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wrong place (in immunological terms, such as a site of infection), an immune response 
could potentially be mounted against a self-protein. Correlative data supporting this is 
that Charcot first described MS one generation after Napoleon ordered the cultivation of 
sugar beets to replace imported sugar, due to a blockade
14
. Also, an outbreak of 
“swayback,” a neurological disease in sheep, occurred in lambs in Alberta after their 
mothers were given a beet silage diet
14
. This correlative data forms an interesting 
hypothesis which will have to be confirmed by future studies. 
 
Other groups have attempted to assign a mechanism to the known correlation 
between high latitude and MS, namely that lower vitamin D levels in areas with less 
sunlight drive MS development
15,16
. A study of Iranians living in Tehran (Figure IA) in 
1989 and 2008 showed that incidence increased dramatically over two decades, and a 
3.11 female to male case difference was observed in 2008, an increase over that in 
1989
17
. This relates to vitamin D at two levels: first, urbanization of Iran is increasing and 
Tehran has experienced dramatic population growth, possibly linking a relatively sun-
deprived urban setting with MS, and second, women were required to wear fully 
enveloping dress after the 1979 Islamic Revolution
17
. Increasing urbanization and 
decreased exposure to sunlight are trends across much of the world, and thus could drive 
further cases of this devastating disease. A better understanding of this subject is critical. 
 
With regard to one final publication on the etiology of MS, a PLoS One study of 
Danish cell phone users was conducted to establish the effect of cell phone usage on rates 
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of MS incidence after a study controversially showed that a 900 MHz field from a phone 
caused BBB breakdown in rats
6
. This study established that cell phone usage does not 
appear to correlate with MS, with the possible exception of female users
6
. However, this 
population was underpowered in the study
6
. This area of research illustrates how many 
possibilities have been considered as causative agents for MS. 
 
In addition to environmental factors, there is clearly a genetic component as 
shown by moderate correlation in disease status between identical twins, though genetics 
do not solely determine disease
18
. From this and the previous examples, it becomes clear 
that the cause of MS is likely multifaceted and a rigorous understanding is currently 
beyond our knowledge. 
 
Treatment: Because the etiology of MS remains unclear and targeted 
immunotherapies remain distant, it is imperative that a better understanding of current 
treatments for MS be achieved to use them more effectively and to refine treatments. MS 
treatments, while not curative, can delay disease progression and delay attacks, 
maintaining function. While new MS treatments are being developed and approved by 
the FDA, the current treatments fall into the following general categories: competitive 
inhibitors of self-peptide binding to major histocompatibility complex proteins (MHC, 
recognized with peptide by T cells) (Copaxone?), interferon-β (IFN-β) formulations 
(Avonex, Rebif, Extavia, and Betaseron), trafficking inhibitors (Gilenya and Tysabri), 
chemotherapeutics (Novantrone), and inhibitors of immune cell function (Copaxone, 
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Tecfidera, and IFN-β)19. However, we do not understand many of these drugs’ 
mechanism of action completely, including those based on IFN-β.  
 
The IFN-β drugs can reduce exacerbations, increase time to new exacerbations, 
slow progression of disease, and decrease the number of active lesions
19
. However, the 
mechanism for such efficacy is uncertain. Type I interferons, like IFN-β, are produced by 
the body primarily in the context of viral infection. In this setting, the proinflammatory 
and antiviral features of these cytokines typically predominate, preparing uninfected cells 
to defend against viral infection, as well as recruiting and supporting immune cells. 
However, IFN-β also possesses numerous immunomodulatory functions, such as 
inhibiting antigen presentation to T cells, blocking immune cell proliferation (such as T 
cells), inducing immunosuppressive cytokines, inhibiting Antigen Presenting Cell (APC) 
costimulatory properties, and impairing trafficking of the cells of the immune system 
(Fig. I)
20,21
. These functions likely restrain the interferon response, especially towards the 
end of an infection. In the context of a chronic immune attack, like MS, IFN-β could 
promote the cessation or limitation of the autoimmune response.  Our studies focus on a 
role for IFN-β in the induction of interleukin-10 (IL-10) in effector T cells, which is a 
potential mechanism of self-regulation by autoreactive mediators. In brief, IL-10 can 
block differentiation of T cells, impair proinflammatory cytokine signaling, prevent 
activation of macrophages, block effector function, reduce costimulation, and limit 
antigen presentation (Fig. II)
22
. IFN-β has been shown to induce IL-10 (in dendritic cells) 
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in a manner dependent on cyclic AMP response element binding protein (CREB) and 
inhibition of glycogen synthase kinase  3 (GSK-3) (Fig. III) 
23
. 
 
A previous study has established that IFN-β increases IL-10 protein and mRNA 
levels in both healthy individual and MS patient peripheral blood mononuclear cells 
(PBMCs, essentially lymphocytes and monocytes) in vitro
24
. The same publication 
demonstrated that intramuscular injection of IFN-β induced higher serum IL-1024. Other 
studies have shown that Avonex increases IL-10 mRNA in MS patients’ PBMCs, that 
Avonex also increases IL-10 levels in the cerebrospinal fluid (CSF), and that CSF IL-10 
levels are correlated with clinical of efficacy of Avonex
25,26
. In contrast, Waubant et al. 
showed that serum IL-10 decreases with IFN-β treatment, but that IL-10 was typically 
elevated during the time period when lesions resolved
27
. Thus, there is strong evidence 
that IL-10 plays a role in IFN-β efficacy, but the question is, what population of cells is 
secreting the cytokine? 
 
T cell populations: the markers CD-4 and CD-8 divide the two populations of 
human T cells. CD-4+ T cells are the key regulators of the immune response, 
complementing the (primarily) direct cytotoxic effects of CD-8+ T cells. CD-4+ T cells 
are subdivided into an ever-increasing number of subsets; this brief survey will focus on 
the four major types, T helper type 1, 2, and 17 cells (Th1, Th2, and Th17) and Tregs. 
The characteristic Th1 cell cytokine is IFN-γ, and Th1 cells are considered to be 
relatively inflammatory. They are essential in the optimum activation of macrophages 
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(the tissue resident immune cell responsible for killing pathogens and cleaning debris 
from the tissue) and are (along with Th17 cells) considered to be important in 
Experimental Autoimmune Encephalomyelitis (EAE) model of MS
28
. Th2 cells are less 
inflammatory and mediate a B cell based antibody-response; a stereotypical cytokine for 
Th2 cells is IL-4. Th17 cells make IL-17 (hence the name) and are critical in neutrophil 
recruitment, which are cells similar to macrophages in that they phagocytose pathogens, 
but differ in that they are short lived. While one form of EAE is Th17 cell driven, 
neutrophil recruitment is not observed in MS
28
. Tregs are generally defined by FoxP3 
expression, the master transcription factor of the subtype, and are responsible for 
maintaining tolerance as well as limiting the immune response. Tregs can inhibit 
activation of T cells in contact and non-contact dependent manners. Tregs are considered 
to have a beneficial impact on MS disease (i.e. reduce disease). While these lines are 
elegantly demarcated, the experimental reality blurs lines between cell types. 
 
One manifestation of this is the IL-10+ effector T cell population which has 
gained increasing prominence over the past decade and a half, with publications 
demonstrating that interleukin-4+, interferon-γ+, and interleukin-17+ T cells (T helper 
type 1, 2, and 17) all can make IL-10
29, 30,31
. This contrasts with traditional immunology 
in that inflammatory Th1 and Th17 cells “should not” make an immunosuppressive 
cytokine like IL-10. In fact, it was long believed that onlyTh2 cells made IL-10 (before 
the discovery of Tregs). Del Prete et al. critically rejected the dogma that IL-10 was a 
Th2 cytokine and established that both Th1 and Th2 type cells can secrete it
29
. 
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Additionally, the authors showed that an IL-10+ Th1 cell shows reduced proliferation in 
response to antigen due to IL-10 mediated effects on APCs; IFN-γ production in response 
to antigen was also reduced
29
. While this population could be construed as solely Tregs, 
future publications elucidated that a subset of the population is distinct from the CD25+, 
FoxP3+ conventional regulatory T cell population and is in fact composed of effector T 
cells; their existence has been demonstrated in both humans and mice, though with the 
caveat that some publications have not definitively eliminated the possibility that the cells 
are IFN-γ+/IL-10+/FoxP3+ Treg cells (Fig. IV)30,32,33,34,35,36.  Axtell et al. demonstrated 
that IFN-γ, IL-10, and IFN-β are intimately linked in the EAE model of MS by 
demonstrating that in a model of Th1 driven EAE, IFN-β efficacy required IFN-γ 
signaling and correlated with IL-10 levels
28
. IFN-γ/IL-10+ Th1 cells have been shown to 
provoke less severe disease in the EAE model, when transferred to induce EAE
34
. 
Similarly, TGF-β/IL-6 induced IL-17+/IL-10+ Th17 cells reduced EAE severity30. With 
regard to literature on other contexts in which these populations are important, Jankovic 
et al. demonstrated that IFN-γ+/IL-10+ effector T cells are critical in suppressing 
Toxoplasma survival and negatively regulate IL-12 production by APCs
35
. Another group 
demonstrated that IL-10+ effector T cells are contributors to the chronic infection state 
seen in leishmaniasis, a more negative role
36
. Patients infected with tuberculosis also 
exhibit IFN-γ+/IL-10+ Th1 cells, which likely contribute to the chronic infection state32. 
IL-27, TGF-β, IL-12, and TGF-β plus interleukin-6 all can induce IL-10 in helper T cells 
when provided during activation
31,34,37,38
.A common thread in many of these publications 
is that repeated or further activation of effector T cells can induce IL-10, suggesting that 
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this is a self-regulatory mechanism
34,35,37
. As a corollary, these cells can be beneficial or 
harmful in the state of infection, either by reducing harmful inflammation or allowing the 
maintenance of a pathogen. In an autoimmune disease like MS, the former is naturally the 
relevant case.  
 
IFN-γ+/IL-10+ Th1 cells are a promising area of MS research because of their 
demonstrated importance in the EAE model, the role of IL-10 in IFN-β efficacy in that 
model, and the immunoregulatory properties of IL-10
22,23,34
.  Thus, we hypothesize that 
IFN-β induces IL-10+ Th1 cells in MS patients and that these cells self-and allo-regulate 
to reduce the immune response.  
 
We have addressed this through the use of MS patient PBMC samples pre- and 
post- treatment with IFN-β, which we characterized by flow cytometry and Enzyme 
Linked Immunosorbent Assays (ELISAs) to search for alterations in our population of 
interest. If a role for IFN-γ+/IL-10+ Th1 cells is established, this could also be a means to 
determine how well a patient is responding to treatment at a more nuanced level than 
whether new lesions have developed. These cells could also be studied in the contexts of 
other treatments as a potential biomarker. Additionally, through a better understanding of 
this Th1 cell population, we would potentially contribute to our current understanding of 
MS development and how regulation is disrupted in the disease state. 
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Figure I: Immunomodulatory roles for IFN-β. IFN- β is known to limit 
proliferation of immune cells, to down-regulate antigen presentation, to limit 
costimulation, to induce cytokines like IL-10 with immunoregulatory function, 
and to down-regulate adhesion molecules and matrix metalloproteases, which 
are required for entry by T cells into tissues
19
. Figure from Yong, V et al
19
.  
14 
 
 
 
 
 
 
 
Figure II: 
Immunomodulation by 
IL-10.  IL-10 possesses 
numerous means to 
suppress the immune 
response. Fig. III depicts 
some of these functions 
with solid gray bars 
indicating suppression 
of signaling by IL-10. 
The cytokine can block 
macrophage to T cell 
and macrophage to NK 
crosstalk, impair 
macrophage activation, 
and disrupt 
differentiation of T 
cells
22
. Figure from 
Moore, K et al
22
. 
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Figure III: A potential mechanism for the induction of IL-10 by IFN-β. Inhibition 
of GSK-3 and CREB activity have been shown to be required for IFN-β induction 
of IL-10 in dendritic cells
23
. Does the same hold true in T cells? Figure adapted 
from Wang, H et al
23
. 
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Figure IV: Th1 and Treg populations. A naïve T cell (Th0) can differentiate into multiple cell 
types, including those herein discussed. Conventional Th1 cells are IFN-γ+, Tbet+ (the 
characteristic Th1 transcription factor). Conventional Tregs are FoxP3+, CD25+ , often IL-
10+. The focus of this study are CD-4+, FoxP3-, CD25-, IL-10+, IFN-γ+, Tbet+ effector Th1 
cells, which appear to be derived from conventional Th1 cells in a manner promoted by 
reactivation and certain cytokines. “Th1 type” regulatory T cells are IFN-γ+,Tbet+, 
FoxP3+,CD25+, often IL-10+. This population has uncertain origins. 
17 
 
 
 
Chapter 2: Methodology 
 
Peripheral blood mononuclear cell (PBMC) culture: MS patient PBMC 
samples were available from pre-treatment to up to 4 years of post-treatment depending 
on the patient. PBMCs encompass primarily lymphocytes (T cells, B cells, and Natural 
Killer cells) and monocytes (which give rise to macrophages). All samples were collected 
at the University of Texas Southwestern and stored in liquid nitrogen. Copaxone treated 
patient samples were obtained from a double blind study, thus copaxone stimulation was 
used to assay proliferation to determine which patients received placebo versus copaxone. 
Patient cohorts: 3 relapsing/remitting MS patients treated with IFN-β (Avonex or 
Betaseron) and 2 primary progressive MS patients treated with Copaxone. A mixed 
population of T lymphocytes and other cells was obtained by thawing the cells and 
resting the total population from 2-4 hours to remove adherent cells and to allow dead 
cells to clump for removal. Cells were cultured in human media (500 milliliters (mL) 
RPMI 1640, 5 mL 1 molar Hepes, 5 mL 10,000 International Units/mL Penicillin/10,000 
micrograms/mL Streptomycin, 5 mL 200 millimolar L-Glutamine, and 25 mL heat 
inactivated Human Serum) with or without anti-CD-3 antibody stimulation. Anti-CD-3 
antibody directly activates the T cell receptor complex without specific engagement of 
the receptor. While memory T cells, which have been previously activated, do not require 
additional stimulation, naïve, antigen-inexperienced T cells (Th0) require costimulation, 
18 
 
which can be provided with anti-CD-28 antibody. As we wished to study only the 
memory T cell population, we only provided anti-CD-3 stimulation. 
 
Flow cytometry: After ~44 hours, PMA/Ionomycin was added to the anti-CD-3 
treated condition to further enhance cytokine production (PMA is an activator of protein 
kinase C, while ionomycin is a calcium channel, both of which activate T cells). After 
one hour, GolgiStop (contains monesin) was added to block export of proteins from the 
Golgi, which aided detection of intracellular cytokines. Four hours later, supernatants and 
cells were collected separately for analysis by ELISA and flow cytometry. Flow 
cytometry consists of staining cells with fluorophore-tagged antibodies specific for 
different markers. The cells are then run through excitatory lasers one at a time to analyze 
levels of each marker on an individual cell through exciting the fluorophores. Flow 
cytometry staining groups consist of compensation controls, isotype controls, and test 
samples. Our compensation controls used unstimulated cells cultured in parallel with 
activated populations and were either unstained or stained with a single antibody. 
Unstained cells allow calibration of the voltages for the excitatory lasers used in flow 
cytometry so that positive population is within the range of detection. Single antibody 
stained controls allow compensation for overlap between different fluorophores’ 
emission spectra. An isotype control consists of a non-specific antibody of the same 
isotype as the antibody for the marker of interest, which yields a value for background 
fluorescence. The markers of interest were: CD-8, CD-3, IL-10, IL-17, and IFN-γ. CD-3 
and CD-8 are markers of T cells and cytotoxic T cells, respectively. By gating on the CD-
19 
 
3+ (T cell), CD-8- (CD-4+ T cell) population, we were able to study CD-4+ T cells, our 
population of interest (Fig. V). Direct gating on CD-4 was not possible because the strong 
activation seen with our conditions resulted in down-regulation of CD-4. Intracellular 
staining was made possible through the use of a fixation and permeabilization kit. Before 
each antibody staining step, cells were treated with Fc block, a reagent which binds to the 
receptors for antibodies on the cells. Without this, antibodies would be non-specifically 
retained by cells. All samples were run on a BD FACSCanto II and all analysis was 
conducted with FlowJo. A note on gating, whenever the compact double negative 
population on IFN-γ+/IL-10+ or IL-17+/IL-10+ plots extended beyond the gate set by the 
isotype, gates were conservatively extended to encompass the entire population. 50,000 
events were collected if possible, each event representing one cell. A flow scatterplot 
with respect to markers A and B has four quadrants, A-B-, A+B-, A+B+, and A-B+, 
clockwise from the bottom left. Each point on a scatterplot represents an individual cell. 
If a levels of a given marker on a cell fall above the background level determined by the 
isotype control, that cell is considered to be positive.
20 
 
 
 
 
 
 
 
 
 
 
Figure V: Gating strategy. Forward Scatter (FSC, Size) and Side Scatter (SSC, Granularity) were used to gate on 
living cell populations (high SSC, low FSC are dead cells). Using the population selected by the FSC vs. SSC 
gate, CD-3 vs. CD-8 gating was used to select CD-3+,CD-8- cells, which are CD-4+ T cells. Isotype controls were 
used to set the threshold for a positive signal above background fluorescence in the population yielded by CD-3 
vs. CD-8 gating. Thus, any cell in the test sample appearing as positive for a cytokine via this gating methodology 
will be alive, CD-4+, and exhibit greater than background staining for the cytokine. As noted in the text, gates 
were increased if the double negative population for IL-10 vs. IFN-γ were above the threshold set in accordance 
with the isotype. For rightmost isotype scatterplot, X axis APC fluorophore, Y axis PE fluorophore.  
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Enzyme linked immunosorbent assays (ELISAs): A technique using antibodies 
to detect levels of a specific protein with high accuracy and precision. To assay protein 
secretion levels, supernatants were collected from all samples, initially with slight PBS 
dilution due to washing the cells out of the wells and subsequently by withdrawing 
supernatants from wells without disturbing the cells. Protein levels were analyzed in our 
study by sandwich ELISAs, which involved coating a well with an antibody specific for 
the protein of interest, adding a sample which may or may not have contained that 
sample, and treating with another antibody specific for a different epitope (or binding 
site) on that protein. The second antibody was conjugated to biotin, which subsequently 
was exposed to a peroxidase-avidin conjugate (avidin and biotin bind in a high affinity 
manner). Addition of substrates ABTS and hydrogen peroxide led to a peroxidase-
mediated electron transfer reaction from ABTS to H2O2 resulting in an ABTS product 
with a bright green color, which was quantified. Through the use of a dilution series of 
the protein of interest to construct a standard curve of concentration to absorbance, each 
of the experimental samples was plotted onto the standard curve to determine its 
concentration. ELISAs were conducted with duplicate samples. 
 
3
H Thymidine proliferation assays: Cells were activated with α-CD-3 antibody 
alone and, after 48 hours, radioactive tritiated thymidine was added. As one of the four 
DNA nucleotides, thymidine, radioactive or not, is incorporated into DNA by 
proliferating cells. Thus, through provision of 
3
H thymidine, total proliferation can be 
assessed by reading the total amount of radioactive thymidine taken up by cells. The cells 
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were harvested 18-24 hours later and radioactivity was quantified with a PerkinElmer 
TopCount NXT to determine proliferation. This assay was used to both confirm T cell 
activation while our methodology was being developed and to determine whether PBMC 
samples from the Copaxone study were from patients treated with placebo or copaxone. 
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Chapter 3: Results 
 
Our first result was the identification of anti-CD-3 antibody treatment plus 
PMA/Ionomycin stimulation as optimal for inducing IL-10, IL-17, and IFN-γ production. 
As human cells exhibit extensive variation and are extremely sensitive to conditions, 
optimizing their treatment for maximal cytokine expression was essential to our studies. 
By comparing anti-CD-3 antibody, PMA/Ionomycin, and anti-CD-3 
antibody+PMA/Ionomycin conditions, we were able to identify the last as conducive to 
maximal cytokine expression. This is logical as the most powerful activating conditions 
are likely to induce higher cytokine levels. 
 
The second step was selecting appropriate antibodies and optimizing flow 
cytometry protocols. Flow cytometry antibody selection depends both on using an 
available fluorophore and using an antibody clone that specifically and accurately 
quantitates levels of the marker of interest. We conducted separate staining for IL-17 and 
IFN-γ in parallel to allow use of the PE fluorophore for both, as it provides the best 
staining. For IL-10, APC was used. For CD-8, FITC, and for CD-3, PerCP. Future 
experiments in progress use AlexaFluor405 and preceeding ones used eFluor450, 
illustrating how quickly the 8 channels for colors on a flow cytometer can become 
occupied. Additionally, the intracellular staining protocol for flow cytometry makes 
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staining a long and complex procedure. Considerable time and resources were devoted to 
troubleshooting this technique. 
 
To address whether IFN-γ+/IL-10+ double positive Th1 cells are induced by IFN-
β treatment, we reactivated memory T cells from MS patients treated with Avonex or 
Betaseron as described and profiled the total population by flow cytometry with respect 
to IL-10, IL-17, and IFN-γ to look for changes before and after patient treatment. Flow 
cytometry is quantitative as well as qualitative (at the single cell level) as fluorescence 
intensity increases with bound antibody, which increases with surface marker levels. 
Quadrant gates allow identification of double positive versus single positive populations, 
which is essential to allow us to identify the IFN-γ/IL-10+ double positive population of 
interest. As presented in Fig. V, our gating methodology selected living CD-4+ T cells. 
We did observe all three cytokines of interest, with the highest levels of IL-17and lowest 
of IL-10, as well as the largest single cytokine positive population being IFN-γ+ and 
lowest IL-17+ (Fig. VI). As seen in the IFN-β treated cohort flow cytometry studies, the 
IFN-γ+ population decreases in 2/3 patients, while the population stays roughly constant 
in 1/3. The IL-10+ population decreases in 1/3 and remains approximately constant in 
2/3. The IL-17+ population increases in 1/3, decreases in 1/3, and remains roughly 
constant in 1/3. The IFN-γ+/IL-10+ double positive population decreases in 1/3 and 
remain approximately constant in 2/3. The IL-17+/IL-10+ double positive population is 
at ~0% in all patients at all times.  
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With regard to the second cohort, examining levels of IFN-γ+/IL-10+ double 
positive cells in a copaxone treated population both allowed us to observe whether any 
trend observed was IFN-β specific or not and to potentially contribute to a better 
understanding of copaxone efficacy. An identical methodology was used for this cohort 
as for the other. Maximal levels of cytokines were similar to those observed in the IFN-β 
cohort, as were the population percentages. Within the copaxone treated cohort (Fig. 
VII), the IFN-γ+ population increased in 1/2, while the population stayed roughly 
constant the other patient. The IL-10+ population appears to have remained constant in 
1/2 and decreased in 1/2. The IL-17+ population increased in 1/2 and remained constant 
in the other patient. The IFN-γ+/IL-10+ double positive population is practically 
undetectable and remained roughly constant. The IL-17+/IL-10+ double positive 
population is at ~0% in all patients at all times.  
 
While flow cytometry does quantitate protein levels of cytokines, the cytokines 
observed are retained intracellularly. Thus, examining extracellular cytokine levels in 
supernatants by ELISAs was essential. With regard to the ELISA data for the IFN-β 
cohort (Fig. VIII), all cytokines appeared to be expressed, though IL-10 was at an 
extremely low level. However, no significant differences were detected between patients 
or at different times. As for the previous cohort, in the copaxone cohort, all cytokines 
appeared to be expressed by ELISA (Fig. VIII), though IL-10 was again at an extremely 
low level. However, no significant differences were detected between patients or at 
different times. 
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Figure VI.A: Cytokine profiles from IFN-β treated 
MS patients. Flow cytometry scatterplots from anti-
CD-3/PMA/Ionomycin activated PBMC populations 
from 3 IFN-β (A, B, C) treated RRMS patients. Each 
page contains a single patient’s data. Top to bottom, 
IFN-γ or IL-17 on Y-axis. IL-10 on all X-axes. Left to 
right, pre-treatment to post treatment. Gated as in Fig 
V. Axes are logarithmic. 
Continued 
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Figure VI.B: Cytokine 
profiles from IFN-β treated 
MS patients. Flow 
cytometry scatterplots from 
anti-CD-3/PMA/Ionomycin 
activated PBMC populations 
from 3 IFN-β (A, B, C) 
treated RRMS patients. Each 
page contains a single 
patient’s data. Top to 
bottom, IFN-γ or IL-17 on 
Y-axis. IL-10 on all X-axes. 
Left to right, pre-treatment 
to post treatment.  Gated as 
in Fig. V. Axes are 
logarithmic. 
Continued 
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Figure VI.C: Cytokine 
profiles from IFN-β 
treated MS patients. Flow 
cytometry scatterplots 
from anti-CD-
3/PMA/Ionomycin 
activated PBMC 
populations from 3 IFN-β 
(A, B, C) treated RRMS 
patients. Each page 
contains a single patient’s 
data. Top to bottom, IFN-γ 
or IL-17 on Y-axis. IL-10 
on all X-axes. Left to 
right, pre-treatment to post 
treatment. Gated as in Fig 
V. Axes are logarithmic. 
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Figure VII.A: Cytokine 
profiles from copaxone 
treated MS patients. 
Flow cytometry 
scatterplots from anti-
CD-3/PMA/Ionomycin 
activated PBMC 
populations from 2 
copaxone (A, B) 
treated PPMS patients. 
Each page contains a 
single patient’s data. 
Top to bottom, IFN-γ 
or IL-17 on Y-axis. IL-
10 on all X-axes. Left 
to right, pre-treatment 
to post treatment. 
Gated as in Fig V. Axes 
are logarithmic. 
Continued 
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Figure VII.B: Cytokine 
profiles from copaxone 
treated MS patients. Flow 
cytometry scatterplots from 
anti-CD-3/PMA/Ionomycin 
activated PBMC populations 
from 2 copaxone (A, B) 
treated PPMS patients. Each 
page contains a single 
patient’s data. Top to bottom, 
IFN-γ or IL-17 on Y-axis. 
IL-10 on all X-axes. Left to 
right, pre-treatment to post 
treatment. Gated as in Fig V. 
Axes are logarithmic. 
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Figure VIII: ELISA data for copaxone and IFN-β treated 
cohorts. IL-10 (A), IL-17 (B), and IFN-γ (C). Presented 
as ng/mL versus time in months. Data presented is for 
the patients corresponding to flow panels VIA 
(RRMS.BVIA), VIB (RRMS.BVIB), and VIIA 
(PPMS.CVIIA). All samples performed in duplicate.  
Error presented as standard deviation. N=1. Note: VIB 
slightly diluted with PBS (within error). 
A) B) 
C) 
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Chapter 4: Discussion 
 
Our data, thus far, does not confirm our hypothesis. While we did observe IFN-
γ+/IL-10+ double positive cells, we did not see the expected increase in population over 
the course of IFN-β therapy. We have observed, primarily, a general decrease in cytokine 
positive cells over IFN-β therapy, which is one effect of that cytokine. In contrast, 
cytokine positive cells remain constant or even increased in the copaxone patient 
population, as seen with IFN-γ+ cells in Fig. VIIA. However, a difficulty pertinent to 
human studies is the issue of variation: day-to-day within a widely varying environment 
for each individual and between individuals (note a dramatic difference like that between 
the 20% IFN-γ+ cells for the patient in Fig. VIIB compared to the level for the others). 
Another potential flaw within our studies is the fact that only RRMS patients were used 
for the IFN-β studies and only PPMS for the copaxone studies. A more diverse patient 
population and a larger cohort may aid in identifying a role for IFN-γ+/IL-10+ cells in a 
specific patient subset. As illustrated by the literature earlier presented on IL-10 serum 
levels, there have been contradictory reports on serum IL-10
23,26
. This may reflect 
different populations. In the EAE model of MS, it has been shown that only Th1 cell 
driven EAE is responsive to IFN-β, while Th17 cell driven EAE is enhanced by IFN-β28. 
While it has not been shown that there a corresponding patient populations in MS, the 
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general principle of differing patient populations with different responses to IFN-β holds 
true. A larger cohort increases the chance of sampling the relevant populations.  
 
Another direction our studies are taking is examining Tbet levels in IFN-γ+/IL-
10+ cells. Tbet is the characteristic Th1 cell transcription factor and has been correlated 
with encephalogenicity in EAE
39
. By studying Tbet, we can further understand whether 
encephalogenic potential changes with IFN-β treatment in our target population. 
Currently, studies are ongoing to characterize Tbet levels in these cells, which may 
identify a Tbet
lo
, IL-10+, IFN-γ cell subset, for example, that correlates with therapeutic 
efficacy. Future studies could also incorporate CFSE staining, a technique which 
measures dilution of the CFSE dye with each division of a cell, allowing further 
subdivision of populations. This would allow us to study whether the IFN-γ/IL-10+ 
population is overrepresented amongst the proliferative cells, as Huss et al demonstrated 
that, in the EAE model, this population is proliferative
34
. A role for IL-10+ Th1 cells in 
MS remains critical to elucidate because of the potential for therapeutic developments 
and biomarkers. Through further studies with an expanded cohort, we hope to identify a 
role for this population in amelioration of disease. 
 
 The importance of these studies lies in the potential to restore self-regulation by 
enhancing this population of IFN-γ+/IL-10+ Th1 cells. It has been demonstrated in mice 
that this population has therapeutic benefit and appears to be induced by chronic 
reactivation in a CNS-like environment
34
. Thus, this appears likely to be a major self-
34 
 
regulatory mechanism. The fact that chronic infections exhibit IL-10+ effector T cell 
populations suggests that T cells default into this pathway in a chronic immune 
response
32,36
. In MS, such regulation must break down. Th1 cells are likely leading 
contributors to disease in MS, and by restoring their self-regulation, immunological 
equilibrium could be restored in patients. It is highly likely that only a subset of patients 
would exhibit such an effect, as over 30% of MS patients do not benefit from IFN-β 
therapy
28
. But by identifying this population, our studies could spur research in this 
direction and provide a basis for the use of IFN-γ+/IL-10+ cells as a biomarker for 
therapeutic efficacy. Such information would allow targeted use of appropriate therapies 
to specific patient populations. Our study also is furthering the study of IL-10+ effector T 
cells and promoting a better understanding of their role in human biology. Our techniques 
can be used to study other disease states in MS and other treatments, while it can also be 
extrapolated to other diseases. Through this study, we have elucidated a means to study 
human IFN-γ+/IL-10+ Th1 cells in disease.  
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